Tesaro joins up with AnaptysBio to develop cancer immunotherapies


Tesaro (TSRO) has signed a global licensing deal with privately held AnaptysBio for a portfolio of antibodies that could be used to develop cancer immunotherapies.

Tesaro will pay AnaptysBio $17M up front and development costs. For each development project, Tesaro will pay $18M in R&D milestones and $90M related to regulatory progress. AnaptysBio will also receive royalties on any product sales. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs